Photo of Maria Bock

Maria Bock

Maria represents clients during mergers, acquisitions and other corporate transactions, counseling companies on all aspects of transactional matters. She has experience with lower middle market, venture capital, private equity and small business transactions, as well as experience advising emerging and existing companies on corporate structure, financing and governance. Fascinated by how organizations function, Maria loves diving deep into an organization and deep into a transaction, determining the best way to deliver a finished product that meets strategic needs and moves the client forward.

This post is the fifth in our five-part series, Navigating Life Sciences Transactions, where our team of attorneys provides essential strategies and insights for successful life sciences transactions.

Throughout this series, we’ve explored the key elements of successful life sciences transactions—from structuring collaborations and securing funding to protecting intellectual property and navigating regulatory complexities.

Yet, even when companies understand these fundamentals, transactions don’t always go as planned. In our work with biotech, medtech, digital health, and research-driven companies, we’ve seen common missteps that can slow deals down, create compliance risks, or weaken long-term business outcomes.

This post is the second in our five-part series, Navigating Life Sciences Transactions, where our team of attorneys provides essential strategies and insights for successful life sciences transactions.

What Investors Look for in Early and Late-Stage Funding Rounds and How Regulatory Compliance Impacts Valuation

For early-stage life sciences and health tech companies, raising capital is about more than demonstrating scientific promise. Investors are increasingly focused on regulatory preparedness, reimbursement strategy, and risk allocation—factors that can significantly impact valuation and long-term viability.